College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0T5, Canada.
Department of Human Anatomy and Cell Science, College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB R3E 0J9, Canada.
Mol Med Rep. 2017 Oct;16(4):4379-4392. doi: 10.3892/mmr.2017.7186. Epub 2017 Aug 7.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease, which involves the progressive degeneration of motor neurons. ALS has long been considered a disease of the grey matter; however, pathological alterations of the white matter (WM), including axonal loss, axonal demyelination and oligodendrocyte death, have been reported in patients with ALS. The present review examined motor neuron death as the primary cause of ALS and evaluated the associated WM damage that is guided by neuronal‑glial interactions. Previous studies have suggested that WM damage may occur prior to the death of motor neurons, and thus may be considered an early indicator for the diagnosis and prognosis of ALS. However, the exact molecular mechanisms underlying early‑onset WM damage in ALS have yet to be elucidated. The present review explored the detailed anatomy of WM and identified several pathological mechanisms that may be implicated in WM damage in ALS. In addition, it associated the pathophysiological alterations of WM, which may contribute to motor neuron death in ALS, with similar mechanisms of WM damage that are involved in multiple sclerosis (MS). Furthermore, the early detection of WM damage in ALS, using neuroimaging techniques, may lead to earlier therapeutic intervention, using immunomodulatory treatment strategies similar to those used in relapsing‑remitting MS, aimed at delaying WM damage in ALS. Early therapeutic approaches may have the potential to delay motor neuron damage and thus prolong the survival of patients with ALS. The therapeutic interventions that are currently available for ALS are only marginally effective. However, early intervention with immunomodulatory drugs may slow the progression of WM damage in the early stages of ALS, thus delaying motor neuron death and increasing the life expectancy of patients with ALS.
肌萎缩侧索硬化症(ALS)是一种致命的神经退行性疾病,涉及运动神经元的进行性退化。长期以来,ALS 一直被认为是一种灰质疾病;然而,在 ALS 患者中已经报道了白质(WM)的病理改变,包括轴突丢失、轴突脱髓鞘和少突胶质细胞死亡。本综述检查了运动神经元死亡作为 ALS 的主要原因,并评估了神经元-神经胶质相互作用指导下的相关 WM 损伤。先前的研究表明,WM 损伤可能发生在运动神经元死亡之前,因此可以被认为是 ALS 诊断和预后的早期指标。然而,ALS 中早期 WM 损伤的确切分子机制尚未阐明。本综述探讨了 WM 的详细解剖结构,并确定了几个可能与 ALS 中 WM 损伤有关的病理机制。此外,它还将与 WM 损伤相关的 WM 的病理生理改变与多发性硬化症(MS)中涉及的类似机制联系起来。此外,使用神经影像学技术早期检测 ALS 中的 WM 损伤可能会导致更早的治疗干预,使用类似于复发缓解型 MS 中使用的免疫调节治疗策略,旨在延缓 ALS 中的 WM 损伤。早期治疗方法可能有潜力延迟运动神经元损伤,从而延长 ALS 患者的生存时间。目前用于 ALS 的治疗干预措施仅略有效果。然而,早期使用免疫调节药物可能会减缓 ALS 早期 WM 损伤的进展,从而延迟运动神经元死亡并增加 ALS 患者的预期寿命。